PharmNovo strengthening the team!

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager, both from KLIFO, to continue the development of the… Read More

PharmNovo appoints CFO and Clinical lead to strengthen the Team!

PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the… Read More

PharmNovo starts clinical phase I studies for its lead candidate for treatmemt of neuropathic pain.

The drug candidate PN6047 from PharmNovo is an entirely new drug. The substance is a selective delta opioid, a so-called DORA (delta opioid receptor agonist),… Read More

PharmNovo raised 67 MSEK in new funding!

PharmNovo is pleased to announce that we have raised 67 MSEK in a new share issue led by Sciety. Other significant investors include Karolinska Development,… Read More

PharmNovo has submitted a Clinical Trial Application (CTA) for its lead candidate for treatment of neuropathic pain.

PharmNovo AB is pleased to announce that a Clinical Trial Application (CTA) has been submitted to the Swedish Medical Products Agency (MPA) as well as… Read More